Literature DB >> 33477152

Duchenne and Becker Muscular Dystrophies' Prevalence in MD STARnet Surveillance Sites: An Examination of Racial and Ethnic Differences.

Yanan Zhang1, Joshua R Mann2, Katherine A James3, Suzanne McDermott1, Kristin M Conway4, Pangaja Paramsothy5, Tiffany Smith6, Bo Cai1.   

Abstract

INTRODUCTION: Previous studies indicated variability in the prevalence of Duchenne and Becker muscular dystrophies (DBMD) by racial/ethnic groups. The Centers for Disease Control and Prevention's (CDC) Muscular Dystrophy Surveillance, Tracking, and Research network (MD STARnet) conducts muscular dystrophy surveillance in multiple geographic areas of the USA and continues to enroll new cases. This provides an opportunity to continue investigating differences in DBMD prevalence by race and ethnicity and to compare the impact of using varying approaches for estimating prevalence.
OBJECTIVE: To estimate overall and race/ethnicity-specific prevalence of DBMD among males aged 5-9 years and compare the performance of three prevalence estimation methods.
METHODS: The overall and race/ethnicity-specific 5-year period prevalence rates were estimated with MD STARnet data using three methods. Method 1 used the median of 5-year prevalence, and methods 2 and 3 calculated prevalence directly with different birth cohorts. To compare prevalence between racial/ethnic groups, Poisson modeling was used to estimate prevalence ratios (PRs) with non-Hispanic (NH) whites as the referent group. Comparison between methods was also conducted.
RESULTS: In the final population-based sample of 1,164 DBMD males, the overall 5-year prevalence for DBMD among 5-9 years of age ranged from 1.92 to 2.48 per 10,000 males, 0.74-1.26 for NH blacks, 1.78-2.26 for NH whites, 2.24-4.02 for Hispanics, and 0.61-1.83 for NH American Indian or Alaska Native and Asian or Native Hawaiian or Pacific Islander (AIAN/API). The PRs for NH blacks/NH whites, Hispanics/NH whites, and NH AIAN/API/NH whites were 0.46 (95% CI: 0.36-0.59), 1.37 (1.17-1.61), and 0.61 (0.40-0.93), respectively.
CONCLUSIONS: In males aged 5-9 years, compared to the prevalence of DBMD in NH whites, prevalence in NH blacks and NH AIAN/API was lower and higher in Hispanics. All methods produced similar prevalence estimates; however, method 1 produced narrower confidence intervals and method 2 produced fewer zero prevalence estimates than the other two methods.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Duchenne-Becker muscular dystrophy; Epidemiology; Race/ethnicity

Mesh:

Year:  2021        PMID: 33477152      PMCID: PMC8045764          DOI: 10.1159/000512647

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  30 in total

Review 1.  Duchenne muscular dystrophy.

Authors:  Eppie M Yiu; Andrew J Kornberg
Journal:  J Paediatr Child Health       Date:  2015-03-09       Impact factor: 1.954

2.  Genetic-epidemiological studies in progressive muscular dystrophy.

Authors:  J Prot
Journal:  J Med Genet       Date:  1971-03       Impact factor: 6.318

3.  Prevalence and Genetic Profile of Duchene and Becker Muscular Dystrophy in Puerto Rico.

Authors:  Edwardo Ramos; José G Conde; Rafael Arias Berrios; Sherly Pardo; Omar Gómez; Manuel F Mas Rodríguez
Journal:  J Neuromuscul Dis       Date:  2016-05-27

4.  The Problem of Rarity: Estimation of Prevalence in Rare Disease.

Authors:  Stéphane Auvin; John Irwin; Paul Abi-Aad; Alysia Battersby
Journal:  Value Health       Date:  2018-04-05       Impact factor: 5.725

5.  Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden.

Authors:  N Darin; M Tulinius
Journal:  Neuromuscul Disord       Date:  2000-01       Impact factor: 4.296

6.  Genetic epidemiology of Duchenne and Becker muscular dystrophy in Slovenia.

Authors:  B Peterlin; J Zidar; M Meznaric-Petrusa; N Zupancic
Journal:  Clin Genet       Date:  1997-02       Impact factor: 4.438

7.  The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use.

Authors:  J Jeppesen; A Green; B F Steffensen; J Rahbek
Journal:  Neuromuscul Disord       Date:  2003-12       Impact factor: 4.296

8.  Progressive muscular dystrophy in Denmark. Natural history, prevalence and incidence.

Authors:  A Leth; K Wulff; M Corfitsen; J Elmgreen
Journal:  Acta Paediatr Scand       Date:  1985-11

9.  Duchenne and Becker muscular dystrophy prevalence in South Africa and molecular findings in 128 persons affected.

Authors:  R Ballo; D Viljoen; P Beighton
Journal:  S Afr Med J       Date:  1994-08

10.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

View more
  3 in total

1.  Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Authors:  Pangaja Paramsothy; Yinding Wang; Bo Cai; Kristin M Conway; Nicholas E Johnson; Shree Pandya; Emma Ciafaloni; Katherine D Mathews; Paul A Romitti; James F Howard; Catharine Riley
Journal:  Neuromuscul Disord       Date:  2022-04-30       Impact factor: 3.538

2.  Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance.

Authors:  Kavya S Nair; Donovan J Lott; Sean C Forbes; Alison M Barnard; Rebecca J Willcocks; Claudia R Senesac; Michael J Daniels; Ann T Harrington; Gihan I Tennekoon; Kirsten Zilke; Erika L Finanger; Richard S Finkel; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  J Neuromuscul Dis       Date:  2022

3.  Characteristics of Clinical Trial Participants with Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Authors:  Katherine D Mathews; Kristin M Conway; Amber M Gedlinske; Nicholas Johnson; Natalie Street; Russell J Butterfield; Man Hung; Emma Ciafaloni; Paul A Romitti
Journal:  Children (Basel)       Date:  2021-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.